BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5 th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in San Diego, CA. Details are as follows: 5 th Annual ALS Drug Development Sum

The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services French Ministry approval recognizes Intravacc as a private research organization for CIR-related R&D expenses for 2025, 2026 and 2027. French biotech and pharmaceutical partners may declare qualifying R&D operations outsourced to Intravacc under the CIR framework, subject to project-level eligibility and applicable rules. Intravacc combines viral, bacteria

Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations Trial-in-Progress Abstract Details Ongoing Phase 2 EVANGELINE Study of (Z)-Endoxifen Plus Goserelin as Neoadjuvant Therapy in Premenopausal Women With ER+/HER2- Breast Cancer SEATTLE , May 27, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel

WATERTOWN, Mass.--(BUSINESS WIRE)-- Nocion Therapeutics, Inc. , a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced the appointment of Vineet Agarwal, MBA as Chief Business Officer. Mr. Agarwal is a recognized life sciences leader, operator and advisor with nearly two decades of experience in company creation, capital formation, and strategic transactions. “We are delighted to welcome Vineet to Nocion. Vineet s

Unlocking Cell Fate: Alliance will power AI-driven predictive medicine and human cell manufacturing SEATTLE--(BUSINESS WIRE)-- Parse Biosciences , the leading provider of scalable and accessible single cell sequencing solutions, today announced an alliance with bit.bio to create a comprehensive map of transcription factor-driven cell identity, encompassing both cell state and cell fate. This map will serve as the foundational blueprint for developing highly accurate, human-relevant models at s

First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetes Integrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providers Designed for compatibility with leading automated insulin delivery (AID) systems ABBOTT

Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP) DSAP is a serious, rare, premalignant genetic skin disease affecting an estimated more than 50,000 diagnosed patients in the U.S., with no FDA-approved therapies Palvella plans to initiate a Phase 2 clinical trial of QTORIN™ pitavastatin in DSAP in the second half of 2026 WAYNE, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Palvel

Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide at 24 weeks GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2

Validation on an independent cohort confirms superior accuracy in detecting MASH with F2/F3 fibrosis, the stages where therapy is now approved FOSTER CITY, Calif.--(BUSINESS WIRE)--Hepta, a liquid biopsy company developing blood tests for chronic disease, today announced clinical data showing its blood test more accurately identifies metabolic dysfunction-associated steatohepatitis (MASH) patients eligible for treatment than the three non-invasive tests recommended by current clinical guidelines

Experienced physician-scientist and life science executive, Dr. Redig will steer InduPro's development strategy as the Company advances its lead program toward Phase 1 Studies SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced the appointment of Amanda J. Redig, MD, PhD, as Chief Medical Officer. A medical oncologist an